Eli Lilly/$LLY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Ticker
$LLY
Sector
Primary listing
NYSE
Employees
47,000
Headquarters
Website
Eli Lilly Metrics
BasicAdvanced
$658B
47.90
$15.29
0.44
$5.60
0.82%
Price and volume
Market cap
$658B
Beta
0.44
52-week high
$951.58
52-week low
$623.78
Average daily volume
5.8M
Dividend rate
$5.60
Financial strength
Current ratio
1.278
Quick ratio
0.512
Long term debt to equity
186.686
Total debt to equity
217.891
Dividend payout ratio (TTM)
36.46%
Interest coverage (TTM)
25.14%
Profitability
EBITDA (TTM)
25,005.6
Gross margin (TTM)
82.64%
Net profit margin (TTM)
25.91%
Operating margin (TTM)
43.40%
Effective tax rate (TTM)
18.15%
Revenue per employee (TTM)
$1,130,000
Management effectiveness
Return on assets (TTM)
16.72%
Return on equity (TTM)
86.29%
Valuation
Price to earnings (TTM)
47.904
Price to revenue (TTM)
12.371
Price to book
35.95
Price to tangible book (TTM)
99.63
Price to free cash flow (TTM)
1,195.518
Free cash flow yield (TTM)
0.08%
Free cash flow per share (TTM)
0.613
Dividend yield (TTM)
0.76%
Forward dividend yield
0.82%
Growth
Revenue change (TTM)
36.83%
Earnings per share change (TTM)
88.31%
3-year revenue growth (CAGR)
22.36%
10-year revenue growth (CAGR)
10.50%
3-year earnings per share growth (CAGR)
34.61%
10-year earnings per share growth (CAGR)
23.01%
3-year dividend per share growth (CAGR)
15.23%
10-year dividend per share growth (CAGR)
10.96%
What the Analysts think about Eli Lilly
Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.
Bulls say / Bears say
Eli Lilly raised its full-year 2025 sales guidance by $2 billion to $60–62 billion and lifted adjusted EPS forecasts to $21.75–23.00, driven by Zepbound’s market share climbing to 57% in the U.S. GLP-1 market (Reuters).
Late-stage data showed Orforglipron achieved an average 10.5% body-weight reduction and 75% A1C control in type 2 diabetes patients over 72 weeks, supporting plans for expedited FDA review and potential blockbuster status as the first oral incretin therapy (Reuters).
The acquisition of Versanis for up to $1.93 billion secures bimagrumab, a novel obesity treatment that preserves lean mass, diversifying Lilly’s cardiometabolic pipeline and complementing its existing GLP-1 franchise (Reuters).
Orforglipron’s Phase 3 trial delivered an average 12.4% weight loss—below Wall Street’s 13–15% expectations and Novo’s 14.9%—prompting a 14.2% share drop and analyst downgrades of its sales outlook (Financial Times).
President Trump’s executive orders and subsequent letters to 17 pharma CEOs, including Eli Lilly’s, demanding “most-favored-nation” pricing and threatening regulatory action if U.S. drug prices aren’t cut have injected uncertainty into Lilly’s pricing power and margins (Reuters).
The oral GLP-1 weight-loss market is set to become crowded with late-stage entrants—Lilly’s Orforglipron, Novo’s oral semaglutide and others—likely sparking intense price competition and potential margin erosion (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 28 Aug 2025.
Eli Lilly Financial Performance
Revenues and expenses
Eli Lilly Earnings Performance
Company profitability
Eli Lilly News
AllArticlesVideos
Novo's Wegovy Beats Lilly's Zepbound for Heart Health, Study Finds. What It Means for Stocks.
Barrons·1 day ago
Novo Nordisk Says Wegovy Cuts Heart Risk by 57% Compared With Eli Lilly's Obesity Drug
WSJ·1 day ago
Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study
Reuters·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Sept10
Eli Lilly
Dividend·Payment
$1.50Per share
FAQs
What’s the current market cap for Eli Lilly stock?
Eli Lilly (LLY) has a market cap of $658B as of September 02, 2025.
What is the P/E ratio for Eli Lilly stock?
The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 47.9 as of September 02, 2025.
Does Eli Lilly stock pay dividends?
Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of September 02, 2025, the dividend rate is $5.6 and the yield is 0.82%. Eli Lilly has a payout ratio of 36.46% on a trailing twelve-month basis.
When is the next Eli Lilly dividend payment date?
The next Eli Lilly (LLY) dividend payment is scheduled for September 10, 2025.
What is the beta indicator for Eli Lilly?
Eli Lilly (LLY) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.